stockrow
Friday 6 November 2026
Export DARE’s income statement to Excel — free account
Dare Bioscience, Inc.
DARE Healthcare Biotechnology
Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024.
- Revenue
- +984.4%
- EPS
- +55.6%
- Free cash flow
- −30.2%
Quarter to June 2026, against a year earlier
0.64
0.02
+3.23%
Follow DARE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | — | — | — | — | — | 10 | 3 | 0 | 1 | 1 | +3.3% | 2 | 7 | 28 | +199.6% | |
| Gross margin, % | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 71.29 | 58.84 | +71.3 pt | ||||||
| EBT | (1) | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (13) | (11) | +39.4% | ||||||
| EBT margin, % | (87.82) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (309.48) | (1,074.16) | (41,363.27) | (1,300.65) | (804.33) | (1,212.8) pt | ||||||
| Net income | (1) | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (13) | (11) | +39.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 11.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 0.39 | 0.00 | 0.09 | 0.09 | (41.2%) | |||||
| Earnings | (9.67) | (42.74) | (18.85) | (11.64) | (10.92) | (7.56) | (4.44) | (4.20) | (0.48) | (1.20) | (0.78) | (20.7%) | ||||||
| Cash flow | (5.35) | (9.44) | (11.49) | (10.26) | (10.07) | (5.65) | (2.57) | (5.34) | 0.64 | (0.88) | (0.76) | (18.1%) | ||||||
| Capex | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | (0.01) | (0.09) | (0.07) | (0.03) | (0.02) | n/m | ||||||
| Free cash flow | (5.35) | (9.44) | (11.50) | (10.26) | (10.07) | (5.65) | (2.58) | (5.43) | 0.58 | (0.92) | (0.78) | (17.8%) | ||||||
| Book value | (10.21) | 49.38 | 7.52 | 0.34 | (0.46) | 7.61 | 1.58 | (0.69) | (0.71) | 0.25 | (0.04) | n/m | ||||||
| Shares, m | 0 | 0 | 1 | 1 | 3 | 5 | 7 | 7 | 8 | 11 | 13 | +75.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | — | — | — | — | — | 0.00 | 2.24 | 2,705.33 | 20.94 | 6.76 | 545.7 | ||||||
| P/B | 0.00 | — | — | — | — | — | 6.60 | 0.00 | 0.00 | 7.59 | 0.00 | 2.8 | ||||||
| EV/Sales | 0.00 | — | — | — | — | — | 0.00 | 2.06 | 1,941.77 | 5.07 | 3.64 | 389.8 | ||||||
| EV/FCF | (21.31) | — | — | — | — | — | (2.59) | (0.67) | 3.88 | (0.51) | (0.43) | (4.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | (3) | (10) | (13) | (25) | (29) | (18) | (39) | 5 | (10) | (11) | +44.0% | |||||
| Capex | (1) | — | 0 | — | 0 | 0 | 0 | (1) | (1) | 0 | 0 | (3.6%) | ||||||
| Free cash flow | 0 | (3) | (10) | (13) | (25) | (29) | (18) | (39) | 5 | (10) | (12) | +44.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (1) | 7 | 6 | 1 | (1) | 39 | 11 | (3) | (3) | 3 | 0 | n/m | |||||
| Net debt | 0 | (8) | (7) | (5) | (5) | (52) | (35) | (10) | (16) | (25) | (13) | +101.8% | ||||||
| Shareholders’ equity | (1) | 13 | 7 | 0 | (1) | 39 | 11 | (5) | (6) | 3 | (1) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (1.72) | (160.83) | (151.57) | (197.16) | (365.59) | (122.15) | (62.12) | (92.65) | (18.69) | (49.10) | (62.16) | (47.4) pt | |||||
| ROIC | 0.00 | (121.89) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (2.80) | (182.85) | (167.23) | (420.05) | 7,710.68 | (205.82) | (124.12) | (994.69) | 73.30 | 845.52 | 165.29 | +848.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 19 | 5 | 14 | 18 | 23 | 28 | 30 | 26 | 23 | 24 | — | +2.6% | |||||
| Revenue/emp, $m | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 | 0.11 | 0.00 | 0.04 | — | +0.7% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Dare Bioscience, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $14.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| BCDA BioCardia, Inc. | $13.5M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −5.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $12.3M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| DARE Dare Bioscience, Inc. | $12.3M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | |
| GUTS Fractyl Health, Inc. | $11.9M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| HIND Vyome Holdings, Inc. | $11.4M | — (loss-making) | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| AEON AEON Biopharma, Inc. | $9.4M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $12.3M | — | — | −57.14% | — | −82.28% | 75.57% | (73.83%) |
Pay and ownership Proxy statement filed 6 October 2026
Ownership
Directors and executive officers, together
3.40%
Law Custodial, Inc.
5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement